The high health care burden faced by individuals with hemophilia underscores the urgent need for innovative treatments and ...

Promising early results from an ongoing randomized, open-label, single-arm, Phase 3 study could pave the way for a Pfizer ...

The approval of concizumab-mtci (Alhemo) injection marks a significant milestone in managing hemophilia A and B with ...

在一项新的研究中，来自印度韦洛尔基督教医学院等研究机构的研究人员发现，慢病毒载体可成功用于为严重血友病A患者提供基因治疗。他们为腺相关病毒（AAV）介导的基因治疗提供了一种潜在的替代方案，解决了将事先存在抗AAV抗体的患者排除在基因治疗对象之外的问题 ...

The FDA recently approved the treatment by Novo Nordisk for hemophilia A or B with inhibitors, designed to prevent or reduce ...

With Alhemo (concizumab-mtci) from Novo Nordisk A/S, a third hemophilia drug in the past eight months has been approved by the U.S. FDA. The once-daily injectable prophylaxis is to prevent or reduce ...

Undeterred by last year’s rejection and the recent approval of a close rival from Pfizer, Novo Nordisk has pushed its ...

Following the apparent elimination of a late-stage gene therapy study last week, Swiss drug juggernaut Roche has confirmed ...

Novo Nordisk (NVO) announced that the U.S. Food and Drug Administration (FDA) has approved its Alhemo (concizumab-mtci) ...

The U.S. Food and Drug Administration has approved Novo Nordisk's drug for the prevention or reduction of bleeding episodes ...

Concizumab is a tissue factor pathway inhibitor antagonist that enhances factor Xa production during the initiation phase of coagulation. This production improves thrombin generation and clot ...

Research led by Christian Medical College in Vellore, India, has demonstrated the successful use of lentiviral vectors to ...